This article was originally published in The Gray Sheet
Executive SummaryBritish firm will return roughly $143.6 mil. ($1.01 per ordinary share) to shareholders following the March 18 acquisition of its stent manufacturing facility by Abbott Labs (1"The Gray Sheet" March 25, 2002, p. 3)...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.